Exhibit 99.2
Lexaria Bioscience Receives Two New Granted Patents
Kelowna, British Columbia October 18, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria), a drug delivery platform innovator, announces it has been granted two new US patents.
Lexaria now has six granted patents in the US and four granted patents in Australia. All ten of these patents are within Lexarias first patent family, Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof. Specifically, the two new patents are related to certain cannabinoid infused beverage compositions utilizing Lexarias proprietary DehydraTECHTM process which continue to strengthen the Companys dominant intellectual property in the important cannabis beverage market.
Newly granted patent numbers 10,103,225 and 10,084,044 provide protection for compositions as well as methods for making the compositions, each of which include the use of both non-psychoactive cannabinoids such as CBD and also psychoactive cannabinoids such as THC. Lexaria is currently pursuing accelerated examination for patent applications in Australia based on these newest US patents and hopes to receive two corresponding Australian patents granted by the end of 2018.
With over 50 patent applications filed worldwide across an increasingly diverse range of patent families, Lexaria continues to expand its patent portfolio as a result of positive developments from its many research projects and is currently preparing additional new applications.
About Lexaria
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexarias
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) | |
and on Facebook http://tinyurl.com/y8vzcaam |
FOR FURTHER INFORMATION PLEASE CONTACT: |
Lexaria Bioscience Corp. |
Alex Blanchard, Communications Manager |
(778) 796-1897 |
Or |
NetworkNewsWire (NNW) |
www.NetworkNewsWire.com |
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional patent protection will be realized or
that patent achievements will deliver material results. Such forward-looking
statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there
can be no assurance that other factors will not affect the accuracy of such
forward-looking statements. Factors which could cause actual results to differ
materially from those estimated by the Company include, but are not limited to,
government regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition, scientific discovery, the patent application
and approval process and other factors which may be identified from time to time
in the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance the Company will be capable
of developing, marketing, licensing, or selling edible products containing
cannabinoids or any other active ingredient. There is no assurance that any
planned corporate activity, scientific research or study, business venture,
technology licensing pursuit, patent application or allowance, consumer study,
or any initiative will be pursued, or if pursued, will be successful. There is
no assurance that any of Lexarias postulated uses, benefits, or advantages for
the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria-associated products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.